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A b s t r a c t
Introduction: Pharmacological treatment combined with lifestyle modifications is an effective treatment for arterial hyper-
tension. However, there are still patients who do not respond to standard treatments. Patients with pharmacologically resistant 
hypertension may benefit from renal denervation (RDN).
Aim: To assess long-term quality of life (QoL) after RDN and effectiveness in reduction of blood pressure (BP) in patients with 
resistant hypertension. 
Material and methods: From 2011 to 2014, 12 patients with previously diagnosed resistant hypertension, treated by RDN, were 
included in this study. The QoL was assessed using a standardized Polish version of the Nottingham Health Profile questionnaire 
(NHP).
Results: The median age was 54 (IQR: 51–57.5) years. Mean baseline ambulatory pre-procedural systolic/diastolic BP was 
188/115 ±29.7/18 mm Hg. The mean values of systolic/diastolic BP measured perioperatively and 3, 6, 12 and 24 months postoper-
atively were 138/86, 138/85, 146/82, 152/86, and 157/91. All p-values for mean systolic and diastolic BP before versus successive 
time points after RDN were statistically significant; p-value for all comparisons < 0.05. Improvement of QoL was only observed in 
two sections of the NHP questionnaire: emotional reaction and sleep disturbance. The analysis of the NHP index of Distress (NHP-D) 
showed a lower distress level perioperatively and 3, 6, 12 and 24 months after RDN as compared to baseline. The RDN was not 
associated with any significant adverse events. 
Conclusions: Patients with pharmacologically resistant hypertension treated with RDN achieved significant reduction in BP 
during 24-month follow-up. Furthermore, a significant improvement in the QoL was observed in those patients.
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Introduction
Renal denervation (RDN) is a percutaneous procedure 
that uses radio-frequency energy to ablate the nerves in 
renal arteries. This method decreases arterial blood pres-
sure (BP), protects against hypertension-related compli-
cations and improves quality of life (QoL). Resistant hy-
pertension is defined as BP that remains above the goal 
in spite of the concurrent use of three optimally dosed 
antihypertensive agents of different classes, one of 
which should be a diuretic [1]. Importantly, an increasing 
number of people are affected by resistant hypertension 
each year [2]. Renal denervation is based on ablation of 
two types of nerves: afferent and efferent. Afferent sig-
naling in the posterior hypothalamus increases central 
sympathetic system activity. The consequences of effer-
ent signaling are activation of the renin-angiotensin-al-
dosterone system and vasoconstriction of renal arteries, 
which results in increased BP values. Recently published 
data on RDN are not consistent. Despite the benefits re-
ported in previous studies [3, 4], the SYMPLICITY HTN-3 
(Renal Denervation in Patients With Uncontrolled Hyper-
tension) clinical trial failed to confirm the effectiveness 
of RDN in patients with resistant hypertension [5]. How-
ever, definitive conclusions on its inefficacy cannot be 
drawn due to a number of study limitations. Also, bene-
fits of RDN may be limited to a selected group of patients 
which has not yet been clearly defined. Fortunately, the 
long-term effectiveness of RDN in terms of BP lowering 
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as well as other clinical endpoints is still under investi-
gation. There is growing interest in the assessment of 
QoL, which seems to be an important outcome measure 
also in patients with resistant hypertension. However, 
QoL with assessment of the treatment effectiveness in 
patients after RDN has not been widely evaluated. In this 
study we analyzed the long-term results (24 months) of 
RDN, and obtained patients’ subjective QoL assessment 
24 months following RDN using the Nottingham Health 
Profile (NHP) questionnaire. The NHP scale is a generic 
QoL questionnaire and is capable of measuring changes 
in perceived health following introduced treatment [6]. 
More importantly, its performance has not reported in 
other studies dealing with the issue of QoL in patients 
with resistant hypertension.
Aim
The aim of the study was to evaluate long-term QoL 
after RDN as well as its effectiveness in reduction of BP 
in patients with resistant hypertension. 
Material and methods
The study group consisted of 12 consecutive patients 
enrolled from January 2011 to December 2014. These 
patients have been diagnosed with resistant arterial hy-
pertension. Resistant arterial hypertension was defined 
as hypertension present despite the concurrent use of 
at least three antihypertensive medications, including 
diuretics. Previously to the procedure and in successive 
follow-up periods after RDN all patients have been regu-
larly taking antihypertensive medications. Patients were 
qualified for RDN and underwent the procedure in accor-
dance with current guidelines [7]. The procedure is per-
formed with the Symplicity renal denervation catheter 
(Medtronic, Minneapolis, MN, USA), which is introduced 
through the femoral artery to the renal arteries bilaterally, 
where it emits radiofrequency energy in range of 5–8 W 
to damage the nerves present in the adventitia of the 
renal artery. The first ablation is applied to the distal part 
of the truncus of the renal artery, and then the catheter 
is withdrawn 5 mm to the outside and rotated around 
90°. Further applications cover all the circuit of the artery 
[8]. Clinical and procedural data were obtained prospec-
tively before the intervention and subsequently during 
in-hospital stay after RDN and at 3, 6, 12 and 24 months 
following the procedure. For the evaluation of QoL, the 
standardized Polish version of the NHP questionnaire 
was used. This questionnaire consists of six sections, 
referring to separate areas of functioning: energy, pain, 
emotional reactions, sleep disturbance, social isolation 
and physical mobility. The NHP index of Distress (NHP-D) 
was devised from the NHP questionnaire, consisting of 
24 yes/no items; higher scores indicate greater distress 
[9]. The follow-up interviews were conducted via tele-
phone before RDN, and 3, 6, 12, and 24 months following 
the procedure. The periprocedural data were obtained 
from the medical history of patients. Blood pressure 
measurements were taken by the patients themselves at 
their place of residence. Patients were asked to provide 
measurements of BP after RDN at least twice a day and 
write down the values. 
Statistical analysis
Standard descriptive statistics were used. The nor-
mality of the data was assessed with the Shapiro-Wilk 
test. Quantitative variables were described using means 
and standard deviations or medians with interquartile 
(IQR) ranges as appropriate. Categorical variables were 
presented as percentages. The Wilcoxon signed-rank test 
(for non-normally distributed data) or paired Student’s 
t-test (for normally distributed data) were applied for 
assessment of changes in particular dimensions of the 
questionnaire and NHP-D at successive time points of 
follow-up. The level of statistical significance was set at 
p ≤ 0.05. All analyses were carried out with the software 
StatSoft, Inc. Statistica (data analysis software system), 
version 10 (Tulsa, OK, USA). 
Results
The median age of included patients was 54 (IQR: 
51–57.5) years. Men constituted 58% (7 patients) of pa-
tients. Four (33%) patients suffered from diabetes melli-
tus, 7 (58%) from hypercholesterolemia, 2 (16.6%) had 
previous stroke and 6 (50%) were active smokers or have 
recently quitted. The mean body mass index (BMI) was 
29.9 ±3.9 kg/m2 with overweight in 5 (41.7%) patients 
and obesity in 5 (41.7%) patients. There was no patient 
with diagnosed obstructive sleep apnea syndrome. The 
mean duration of energy delivery was 18.1 ±6.7 min. The 
mean radiation dose and contrast load were 0.58 ±0.29 Gy 
and 243.57 ±73.3 ml, respectively. The mean number of 
successful ablations applied to the right and left renal 
artery was 6.6 ±4.4 and 5.6 ±1.7, respectively. There were 
no changes in the levels of sodium p = 0.5, potassium 
(p = 0.9), urea (p = 0.5), or creatinine (p = 0.7) after the 
procedure as compared to baseline. There were no pro-
cedure-related complications. No difference between 
kidney function estimated by glomerular filtration rate 
(eGFR) before and after the procedure was found (53 ±9.9 
vs. 55.8 ±8.9 ml; p = 0.4). In the study population there 
was no significant change in the number or type of anti-
hypertensive drugs. Mean baseline pre-procedural systol-
ic/diastolic BP for the whole group was 188/115 ±29.7/ 
18 mm Hg. Median follow-up was 872 (IQR: 499–1187) 
days. The mean BP after the procedure was reduced to 
138/86 ±29.2/19.9, 138/85 ±16.9/8.9, 146/82 ±16.4/5.9, 
152/86 ±14/11.6, and 157/91 ±12.2/10.3 mm Hg periop-
eratively and 3, 6, 12 and 24 months after the procedure, 
respectively. The analysis shows significant differences 
between mean values of pre-procedural BP in compari-
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son with those obtained in successive periods after RDN. 
All p-values for mean systolic and diastolic BP before ver-
sus successive time points after RDN were statistically 
significant; p-value for all comparisons < 0.05. The mean 
value of the highest observed BP before the procedure 
was 229/132 ±37.9/26.5 mm Hg. The maximal BP ob-
tained perioperatively and 3, 6, 12 and 24 months after 
the procedure was 161/98 ±29/21.7, 159/95 ±25.3/17.1, 
166/97 ±26.7/17.9, 177/104 ±24.8/12.4, and 203/121 
±38.4/25.4 mm Hg, respectively. A significant reduction 
of maximum systolic and diastolic BP in comparison with 
baseline was observed perioperatively and 3, 6 and 12 
months following RDN (p-values for maximum systol-
ic and diastolic BP before versus perioperatively and 3, 
6 and 12 months after RDN were < 0.5). This effect was 
not observed 24 months after the procedure (systolic 
and diastolic BP before vs. 24 months after RDN: p = 0.2, 
p = 0.5, respectively). Results are presented in Figure 1.
Table I  shows a  detailed distribution of the scores 
from NHP. A  significant improvement of QoL was ob-
served in the sections of emotional reactions (answers 
of patients before RDN versus all successive periods of 
follow-up) and sleep disturbance (answers of patients 
before RDN versus perioperatively and 3 and 24 months 
following RDN) in the NHP questionnaire. Total score of 
NHP-D was significantly lower perioperatively and at 3, 
6, 12, and 24 months after RDN as compared to baseline. 
Discussion
Patients treated with RDN in the studied group 
achieved significant reduction in mean systolic and dia-
stolic BP during 24-month follow-up and in mean value 
of the highest BP perioperatively and 3, 6 and 12 months 
following the procedure. Patients with resistant hyper-
tension are at a higher risk of cardiovascular events and 
end-organ damage as compared to patients with ade-
quately controlled hypertension [10]. The efficacy of the 
RDN procedure has been assessed in several large stud-
ies. The Symplicity HTN-1 and randomized Symplicity 
HTN-2 trial demonstrated that RDN is feasible, effective 
and safe in the treatment of resistant hypertension. In 
both studies, no adverse effects of RDN on renal function 
were observed [3, 4]. The Symplicity HTN-3 trial suggest-
ed that 6 months after RDN there were no significant dif-
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Figure 1. Mean and maximal systolic and diastolic blood pressure before and after renal denervation: A – mean 
systolic blood pressure, B – mean diastolic blood pressure, C – maximal systolic blood pressure, D – maximal 
diastolic blood pressure. Results presented as mean values (squares), SD (box), and minimum and maximum 
values (whiskers)
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ferences in reduction of systolic BP in office or 24-hour 
ambulatory measurements as compared with a  sham 
control [5]. The results of the Symplicity HTN-3 trial did 
not confirm the results of previous registries and trials 
with a potentially overestimated treatment effect; how-
ever, several limitations of the study design might have 
influenced the clinical outcomes [11–13]. On the other 
hand, Symplicity HTN-3 confirmed the safety of the RDN 
procedure. Based on the results of individual analyses, 
we can conclude that the final effect of RDN will depend 
on many factors and this procedure may not be suitable 
for all patients. Identifying predictors which make RDN 
effective is important to select patients who will respond 
to treatment. Due to important uncertainties about RDN, 
more research is required to provide conclusive evidence 
for antihypertensive long-term effects, safety, clinical 
outcomes and QoL improvement after RDN. The addi-
tional benefits of RDN observed in other studies were 
reduction of left ventricle mass and improvement of di-
astolic function. These might have important prognostic 
implications for patients with resistant hypertension at 
high cardiovascular risk [14]. Other studies have suggest-
ed a reduction in heart rate over 6 months [15, 16], as 
well as a positive effect on renal function [17], glucose 
metabolism and insulin sensitivity [18] after RDN. In the 
present study an improvement in QoL was observed. 
A significantly lower level of distress (NHP-D) and amelio-
ration of the emotional reactions and sleep disturbance 
sections were reported. However, they were not observed 
at all successive time points, probably due to the size of 
the group and possible observational error. The effects of 
RDN in patients with obstructive sleep apnea syndrome 
are the subject of several studies. In these patients hy-
pertension is caused by increased sympathetic overdrive. 
The RDN may provide greater BP reduction and might 
reduce sleep-onset cardiovascular events by suppressing 
hypoxia-induced nocturnal BP peaks [19]. The RDN also 
improves the severity of obstructive sleep apnea syn-
drome in patients with resistant hypertension by a  re-
duction of the apnea-hypopnea index, fewer nocturnal 
awakenings and improvement of nocturnal oxygen satu-
ration [20]. It might explain better outcomes in the sec-
tion of sleep disturbances in the NHP questionnaire after 
the RDN as compared to baseline. The QoL after RDN has 
been assessed in several studies [21–24]. Lenski et al. 
observed reduction of anxiety and depression, intensity 
of headache and improved QoL and stress tolerance in 
119 patients treated with RDN. In that study, the Hospital 
Anxiety and Depression Scale and Short Form-12 Health 
Survey were used to assessed QoL at baseline and at 
3 and 6 months following RDN [21]. In other studies RDN 
improved subjective QoL in several aspects examined by 
Beck Depression Inventory-II and without a detrimental 
effect on any elements of the 36-Item Short-Form Health 
Survey 3 months after RDN. However, there was no cor-
relation between improvement of QoL and the mag-
nitude of BP reduction [22]. A  recently published study 
assessed the effect of RDN on BP and health-related QoL 
12 months after RDN and revealed that RDN in patients 
with confirmed resistant hypertension is associated with 
a reduction in BP and a sustained improvement in mental 
health-related aspects of QoL [23]. Another study report-
ed that sufficient BP reduction by RDN and time follow-
ing therapeutic success lead to significant improvements 
in patient QoL and a loss of anxiety in 93% of recipients 
[24]. Several studies have revealed improvement of the 
QoL using different questionnaires, especially in terms of 
depression and anxiety. It is consistent with our results 
concerning the emotional reactions section and the in-
dex of distress from the NHP questionnaire.
The results of the present study were obtained at one 
center, which potentially limits their generalizability. An-
Table I. Detailed results from Nottingham Health Profile (NHP) Questionnaire 
Variable Before 
RDN
Periopera-
tively
P-valuea 3 months 
after
RDN
P-valueb 6 months 
after
RDN
P-valuec 12 months 
after RDN
P-valued 24 months 
after
RDN
P-valuee
Energy 22.2 ±41.0 8.3 ±20.7 0.2 5.6 ±19.3 0.2 8.3 ±20.7 0.3 25.0 ±32.2 0.8 27.8 ±37.2 0.6
Pain 13.5 ±24.7 15.6 ±28.8 0.7 15.6 ±28.8 0.7 15.6 ±28.8 0.7 15.6 ±27.2 0.7 15.6 ±28.8 0.7
Emotional 
reactions
19.4 ±23.3 9.3 ±13.3 0.02 4.6 ±11.1 0.02 4.6 ±11.1 0.02 5.6 ±11.1 0.02 7.4 ±17.3 0.02
Sleep 
disturbance
40.0 ±37.2 21.7 ±30.1 0.04 21.7 ±30.1 0.04 23.3 ±30.6 0.07 30.0 ±26.3 0.2 23.3 ±32.8 0.03
Social 
isolation
1.7 ±5.8 0 0.3 0 0.3 0 0.3 1.7 ±5.8 1 1.7 ±5.8 1
Physical 
mobility
6.3 ±14.6 9.4 ±17.0 0.3 9.4 ±17.0 0.3 9.4 ±17.0 0.3 10.4 ±16.7 0.2 9.4 ±17.0 0.3
NHP-D 4.2 ±4.7 2.2 ±3.0 0.01 1.7 ±2.9 0.005 1.8 ±2.8 0.006 2.8 ±3.4 0.04 2.8 ±4.5 0.03
Mean values of total score for each section expressed as a percentage and mean values of the NHP index of Distress (NHP-D). Comparison of response before the 
procedure versus perioperatively and at 3, 6, 12 and 24 months after renal denervation (RDN). aBefore RDN vs. perioperatively, bbefore RDN vs. 3 months after RDN, 
cbefore vs. 6 months after RDN, dbefore vs. 12 months after RDN, ebefore vs. 24 months after RDN.
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other limitation is the lack of a control group and small 
sample size related to the limited number of RDN pro-
cedures performed in our center. Twenty-four-month fol-
low- up was not available in all the patients. In addition, 
measurements of BP values were taken by the patients 
themselves at their place of residence, and this fact could 
be a potential source of inaccurate results. Ambulatory 
blood pressure monitoring was not performed. There 
are potential limitations associated with the tool for QoL 
assessment. The NHP is a generic questionnaire which 
is not specific for cardiovascular diseases and interven-
tions. 
Conclusions
Patients with pharmacologically resistant hyperten-
sion treated with RDN achieved significant reduction 
of mean values of BP during 24-month follow-up. Fur-
thermore, a significant improvement in the QoL was ob-
served in the emotional reactions as well as sleep dis-
turbance sections of the NHP questionnaire and in the 
NHP-D.
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